Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population

Table 2 Baseline characteristics of eligible patients

	Total (n = 95)	Oral (n = 57)	Infusional (n = 38)	P value
Gender (%)
Male	52 (54.7)	32 (56.1)	20 (52.6)	0.900
Age (yr)
Median	61.0	61.0	61.0	0.622
Age ≥ 70 (%)	21 (22.1)	12 (21.1)	9 (23.7)	0.960
ECOG performance status
0	7 (7.4)	4 (7.0)	3 (7.9)	0.383
1	80 (84.2)	50 (87.7)	30 (78.9)
2	8 (8.4)	3 (5.3)	5 (13.2)
3	0 (0)	0 (0)	0 (0)
4	0 (0)	0 (0)	0 (0)
Site of primary tumor (%)
Right-sided colon	20 (21.1)	15 (26.3)	5 (13.2)	0.114
Left-sided colon	49 (51.6)	25 (43.9)	24 (63.2)
Rectum	22 (23.2)	13 (22.8)	9 (23.7)
Multiple	4 (4.2)	4 (7.0)	0 (0.0)
Timing of metastasis (%)
Synchronous	72 (75.8)	40 (70.2)	32 (84.2)	0.187
Metachronous	23 (24.2)	17 (29.8)	6 (15.8)
Extent of the disease (%)
Primary resected1	68 (71.6)	42 (73.7)	26 (68.4)	0.745
Liver-only metastatsis	44 (46.3)	26 (45.6)	18 (47.4)	1.000
> 1 site of metastasis	40 (42.1)	24 (42.1)	16 (42.1)	1.000
Site of metastasis (%)
Liver	67 (70.5)	39 (68.4)	28 (73.7)
Lymph Nodes	28 (29.5)	17 (29.8)	11 (28.9)
Peritoneum	21 (22.1)	11 (19.3)	10 (26.3)
Lung	17 (17.9)	11 (19.3)	6 (15.8)
Bone	3 (3.2)	2 (3.5)	1 (2.6)
Others	8 (8.4)	6 (10.5)	2 (5.3)

No significant differences were recognized in the distribution of the baseline patient characteristics between the oral and infusional fluoropyrimidine groups. With regard to the clinical characteristics of the disease and extent of disease, the two groups of patients were comparable in terms of site of primary tumour, resection of primary tumour, timing of the metastasis, and proportion of liver-only disease.

¹Include both palliative surgery of primary and previous surgery of nonmetastatic patients.